Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01768403

Acronym

CEPHEUS

Enrollment

1236

Registered

2013-01-15

Start date

2010-09-30

Completion date

2011-03-31

Last updated

2013-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Coronary Heart Disease, Diabetes, Hypercholesterolemia, Hypertension, Peripheral Arterial Disease

Keywords

Hypercholesterolemia, Cardiovascular disease, Hypertension, Coronary Heart disease, Peripheral Arterial disease

Brief summary

Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.

Detailed description

Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subject must provide informed consent and comply with the survey procedures. * Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion criteria

\- Subjects who are unwilling or unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.	24 weeks

Secondary

Measure	Time frame	Description
Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.	24 weeks	In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients
Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines	24 weeks	Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven
Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.	24 weeks	For the following sub-populations: Demographic variables, CV risk factors & Lipid-lowering agent class
The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models	24 weeks	—

Outcome results